WO2004087737A3 - Omega-3 fatty acid assays for disease risk assessment - Google Patents

Omega-3 fatty acid assays for disease risk assessment Download PDF

Info

Publication number
WO2004087737A3
WO2004087737A3 PCT/US2004/009567 US2004009567W WO2004087737A3 WO 2004087737 A3 WO2004087737 A3 WO 2004087737A3 US 2004009567 W US2004009567 W US 2004009567W WO 2004087737 A3 WO2004087737 A3 WO 2004087737A3
Authority
WO
WIPO (PCT)
Prior art keywords
omega
risk
individual
fatty acid
death
Prior art date
Application number
PCT/US2004/009567
Other languages
French (fr)
Other versions
WO2004087737A2 (en
Inventor
Williams S Harris
Original Assignee
Omegametrix Llc
Williams S Harris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omegametrix Llc, Williams S Harris filed Critical Omegametrix Llc
Publication of WO2004087737A2 publication Critical patent/WO2004087737A2/en
Publication of WO2004087737A3 publication Critical patent/WO2004087737A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Methods for determining an individual’s overall risk of death from coronary heart disease are provided. The methods utilize measurements of the individual’s levels of omega-3 polyunsaturated fatty acids in order to stratify them according to their risk of death from CHD. The risk-stratification can be used to classify the individual’s risk of death from CHD as low, intermediate, or high based on levels of omega-3 fatty acids of 8% or higher, between 4% and 8%, and 4% or below, respectively. The present invention then provides methods of monitoring an individual’s progress toward lowering their risk by periodically measuring their omega-3 levels and instructing the individuals to alter their intake of omega-3 fatty acid-containing foods or supplements.
PCT/US2004/009567 2003-03-26 2004-03-26 Omega-3 fatty acid assays for disease risk assessment WO2004087737A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45800903P 2003-03-26 2003-03-26
US60/458,009 2003-03-26
US61752303A 2003-07-10 2003-07-10
US10/617,523 2003-07-10

Publications (2)

Publication Number Publication Date
WO2004087737A2 WO2004087737A2 (en) 2004-10-14
WO2004087737A3 true WO2004087737A3 (en) 2005-03-17

Family

ID=33135080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009567 WO2004087737A2 (en) 2003-03-26 2004-03-26 Omega-3 fatty acid assays for disease risk assessment

Country Status (1)

Country Link
WO (1) WO2004087737A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178105A1 (en) * 2010-01-15 2011-07-21 E.I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
BR112016025518A2 (en) * 2014-04-29 2017-08-15 Laboratoire Danalyses Medicales Roman Pais Erythrocyte Fatty Acid Dosage Method
DE102016109753B4 (en) 2015-05-29 2024-06-27 Waters Technologies Corporation DETERMINATION OF FREE AND TOTAL FATTY ACIDS USING DESORPTION IONIZATION MASS SPECTROMETRY
CN108108762B (en) * 2017-12-22 2021-03-16 北京工业大学 Nuclear extreme learning machine for coronary heart disease data and random forest classification method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075101A (en) * 1990-04-10 1991-12-24 Siguel Edward N Method for diagnosis of fatty acid or lipid abnormalities
US5326649A (en) * 1991-03-27 1994-07-05 Shin-Etsu Chemical Co., Ltd. X-ray transmitting membrane for mask in x-ray lithography and method for preparing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075101A (en) * 1990-04-10 1991-12-24 Siguel Edward N Method for diagnosis of fatty acid or lipid abnormalities
US5326649A (en) * 1991-03-27 1994-07-05 Shin-Etsu Chemical Co., Ltd. X-ray transmitting membrane for mask in x-ray lithography and method for preparing the same

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CARROLL D.N. ET AL.: "Evidence for the cardioprotective effects of omega-3 fatty acids", THE ANNALS OF PHARMACOTHERAPY, vol. 36, December 2002 (2002-12-01), pages 1950 - 1956, XP008041187 *
GERBER M.J. ET AL.: "Profiles of a healthful diet and its relationship to biomarkers in a population sample from mediterranean southern France", JOURNAL OF AMERICAN DIETETIC ASSOCIATION, vol. 100, no. 10, October 2000 (2000-10-01), pages 1164 - 1171, XP002982646 *
PAGANELLI F. ET AL.: "Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease", INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 78, 2001, pages 27 - 32, XP002982647 *
PALOZZA O. ET AL.: "n-3 fatty acids induce oxidative modifications in human erythrocytes depending on dose and duration of dietary supplementation", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 64, 1996, pages 297 - 304, XP008041188 *
RUSSO C. T AL.: "Omega-3 polyunsaturated fatty acid supplements and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension", JOURNAL OF HYPERTENSION, vol. 13, no. 12, 1995, pages 1823 - 1826, XP008041161 *
SEIDELIN K.N. ET AL.: "N-3 fatty acids in adipose tissue and coronary artery disease are inversely related", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 55, 1992, pages 1117 - 1119, XP000901984 *
SIMOPOULOS A.P.: "Essential fatty acids in health and chronic disease", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 70, 1999, pages 560S - 569S, XP001153940 *
SISCOVICK D.S. ET AL.: "Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest", JAMA, vol. 274, no. 17, 1 November 1995 (1995-11-01), pages 1363 - 1367, XP008041164 *
TYNAN M.B. ET AL.: "Erythrocyte membrane fatty acid composition as a marker of dietary compliance in hyperlipidaemic subjects", ATHEROSCLEROSIS, vol. 117, 1995, pages 245 - 252, XP002982645 *

Also Published As

Publication number Publication date
WO2004087737A2 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
Chiu et al. Associations between n− 3 PUFA concentrations and cognitive function after recovery from late-life depression
Flock et al. Long-chain omega-3 fatty acids: time to establish a dietary reference intake
Harris et al. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids
Tully et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case–control study
Mozaffarian et al. Health effects of trans-fatty acids: experimental and observational evidence
O'Callaghan et al. Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study
Ullegaddi et al. B-group vitamin supplementation mitigates oxidative damage after acute ischaemic stroke
Linden et al. Antioxidants and periodontitis in 60–70‐year‐old men
DE60227951D1 (en) DELTA 4 DESATURASE GENES AND THEIR USE
ATE545702T1 (en) DELTA-5-DESATURASE AND ITS USE IN THE PRODUCTION OF POLYUNSATURATED FATTY ACIDS
ATE544858T1 (en) DELTA-5-DESATURASE AND ITS USE IN THE PRODUCTION OF POLYUNSATURATED FATTY ACIDS
RU2008123861A (en) PRODUCT OF TYPE OF MAYONESIS AND METHOD OF ITS PRODUCTION
Passaro et al. Plasma homocysteine, methylenetetrahydrofolate reductase mutation and carotid damage in elderly healthy women
WO2005093103A3 (en) Development and use of fluorescent probes of unbound analytes
WO2004087737A3 (en) Omega-3 fatty acid assays for disease risk assessment
Majewski et al. Copper nanoparticles enhance vascular contraction induced by prostaglandin F2-alpha and decrease the blood plasma Cu/Zn ratio in Wistar rats
Chakraborty et al. Seasonal and inter-annual lipid dynamics of spiny cheek grouper (Epinephelus diacanthus) in the southern coast of India
Leung et al. Nutritional manipulation of primate retinas. IV. Effects of n− 3 fatty acids, lutein, and zeaxanthin on S-cones and rods in the foveal region
MacQueen et al. Age-related biomarkers can be modulated by diet in the rat
KR20200061344A (en) Non-human model animal of non-alcoholic fatty liver disease
Masi et al. Toxicity of fatty acids on ECV-304 endothelial cells
WO2008147206A3 (en) Means and methods for classifying samples of multiple sclerosis patients
Gogga et al. Lipid profile in Polish women following lacto-ovo-vegetarian and vegan diets–preliminary study.
Wali et al. Antioxidant Vitamins Status Of Hypertensive Subjects In Sokoto, Nigeria
Jackson et al. Assessing the Omega-3 Index in a population: Canada did it right

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase